Therapeutic strategies to correct proteostasis-imbalance in chronic obstructive lung diseases

M. Bodas, I. Tran, N. Vij

Research output: Contribution to journalArticle

Abstract

Proteostasis is a critical cellular homeostasis mechanism that regulates the concentration of all cellular proteins by controlling protein-synthesis, processing and degradation. This includes proteinconformation, binding interactions and sub-cellular localization. Environmental, genetic or age-related pathogenetic factors can modulate the proteostasis (proteostasis-imbalance) through transcriptional, translational and post-translational changes that trigger the development of several complex diseases. Although these factors are known to be involved in pathogenesis of chronic obstructive pulmonary disease (COPD), the role of proteostasis mechanisms in COPD is scarcely investigated. As a proof of concept, our recent data reveals a novel role of proteostasis-imbalance in COPD pathogenesis. Briefly, cigarette-and biomass-smoke induced proteostasis-imbalance may aggravate chronic inflammatory-oxidative stress and/or protease-anti-protease imbalance resulting in pathogenesis of severe emphysema. In contrast, pathogenesis of other chronic lung diseases like ΔF508-cystic fibrosis (CF), α1-anti-trypsin-deficiency (α -1 ATD) and pulmonary fibrosis (PF) is regulated by other proteostatic mechanisms, involving the degradation of misfolded proteins (ΔF508-CFTR/α1-AT-Z variant) or regulating the concentration of signaling proteins (such as TGF-β1) by the ubiquitin-proteasome system (UPS). The therapeutic strategies to correct proteostasis-imbalance in misfolded protein disorders such as ΔF508-CF have been relatively well studied and involve strategies that rescue functional CFTR protein to treat the underlying cause of the disease. While in the case of COPDemphysema and/or PF, identification of novel proteostasis-regulators that can control inflammatory-oxidative stress and/or protease-anti-protease balance is warranted.

Original languageEnglish (US)
Pages (from-to)807-814
Number of pages8
JournalCurrent Molecular Medicine
Volume12
Issue number7
StatePublished - Aug 2012

Fingerprint

Pulmonary diseases
Chronic Obstructive Pulmonary Disease
Peptide Hydrolases
Cystic Fibrosis Transmembrane Conductance Regulator
Pulmonary Fibrosis
Cystic Fibrosis
Oxidative stress
Proteins
Oxidative Stress
Proteostasis Deficiencies
Emphysema
Proteasome Endopeptidase Complex
Therapeutics
Ubiquitin
Degradation
Smoke
Tobacco Products
Biomass
Trypsin
Lung Diseases

Keywords

  • Autophagy
  • Chronic obstructive pulmonary disease (COPD)
  • Cigarette smoke (CS)
  • Emphysema
  • Proteostasis-imbalance
  • Proteostasis-regulators

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Molecular Medicine

Cite this

Therapeutic strategies to correct proteostasis-imbalance in chronic obstructive lung diseases. / Bodas, M.; Tran, I.; Vij, N.

In: Current Molecular Medicine, Vol. 12, No. 7, 08.2012, p. 807-814.

Research output: Contribution to journalArticle

@article{fd88d37e54f14cfea6dcb62becef8e1d,
title = "Therapeutic strategies to correct proteostasis-imbalance in chronic obstructive lung diseases",
abstract = "Proteostasis is a critical cellular homeostasis mechanism that regulates the concentration of all cellular proteins by controlling protein-synthesis, processing and degradation. This includes proteinconformation, binding interactions and sub-cellular localization. Environmental, genetic or age-related pathogenetic factors can modulate the proteostasis (proteostasis-imbalance) through transcriptional, translational and post-translational changes that trigger the development of several complex diseases. Although these factors are known to be involved in pathogenesis of chronic obstructive pulmonary disease (COPD), the role of proteostasis mechanisms in COPD is scarcely investigated. As a proof of concept, our recent data reveals a novel role of proteostasis-imbalance in COPD pathogenesis. Briefly, cigarette-and biomass-smoke induced proteostasis-imbalance may aggravate chronic inflammatory-oxidative stress and/or protease-anti-protease imbalance resulting in pathogenesis of severe emphysema. In contrast, pathogenesis of other chronic lung diseases like ΔF508-cystic fibrosis (CF), α1-anti-trypsin-deficiency (α -1 ATD) and pulmonary fibrosis (PF) is regulated by other proteostatic mechanisms, involving the degradation of misfolded proteins (ΔF508-CFTR/α1-AT-Z variant) or regulating the concentration of signaling proteins (such as TGF-β1) by the ubiquitin-proteasome system (UPS). The therapeutic strategies to correct proteostasis-imbalance in misfolded protein disorders such as ΔF508-CF have been relatively well studied and involve strategies that rescue functional CFTR protein to treat the underlying cause of the disease. While in the case of COPDemphysema and/or PF, identification of novel proteostasis-regulators that can control inflammatory-oxidative stress and/or protease-anti-protease balance is warranted.",
keywords = "Autophagy, Chronic obstructive pulmonary disease (COPD), Cigarette smoke (CS), Emphysema, Proteostasis-imbalance, Proteostasis-regulators",
author = "M. Bodas and I. Tran and N. Vij",
year = "2012",
month = "8",
language = "English (US)",
volume = "12",
pages = "807--814",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Therapeutic strategies to correct proteostasis-imbalance in chronic obstructive lung diseases

AU - Bodas, M.

AU - Tran, I.

AU - Vij, N.

PY - 2012/8

Y1 - 2012/8

N2 - Proteostasis is a critical cellular homeostasis mechanism that regulates the concentration of all cellular proteins by controlling protein-synthesis, processing and degradation. This includes proteinconformation, binding interactions and sub-cellular localization. Environmental, genetic or age-related pathogenetic factors can modulate the proteostasis (proteostasis-imbalance) through transcriptional, translational and post-translational changes that trigger the development of several complex diseases. Although these factors are known to be involved in pathogenesis of chronic obstructive pulmonary disease (COPD), the role of proteostasis mechanisms in COPD is scarcely investigated. As a proof of concept, our recent data reveals a novel role of proteostasis-imbalance in COPD pathogenesis. Briefly, cigarette-and biomass-smoke induced proteostasis-imbalance may aggravate chronic inflammatory-oxidative stress and/or protease-anti-protease imbalance resulting in pathogenesis of severe emphysema. In contrast, pathogenesis of other chronic lung diseases like ΔF508-cystic fibrosis (CF), α1-anti-trypsin-deficiency (α -1 ATD) and pulmonary fibrosis (PF) is regulated by other proteostatic mechanisms, involving the degradation of misfolded proteins (ΔF508-CFTR/α1-AT-Z variant) or regulating the concentration of signaling proteins (such as TGF-β1) by the ubiquitin-proteasome system (UPS). The therapeutic strategies to correct proteostasis-imbalance in misfolded protein disorders such as ΔF508-CF have been relatively well studied and involve strategies that rescue functional CFTR protein to treat the underlying cause of the disease. While in the case of COPDemphysema and/or PF, identification of novel proteostasis-regulators that can control inflammatory-oxidative stress and/or protease-anti-protease balance is warranted.

AB - Proteostasis is a critical cellular homeostasis mechanism that regulates the concentration of all cellular proteins by controlling protein-synthesis, processing and degradation. This includes proteinconformation, binding interactions and sub-cellular localization. Environmental, genetic or age-related pathogenetic factors can modulate the proteostasis (proteostasis-imbalance) through transcriptional, translational and post-translational changes that trigger the development of several complex diseases. Although these factors are known to be involved in pathogenesis of chronic obstructive pulmonary disease (COPD), the role of proteostasis mechanisms in COPD is scarcely investigated. As a proof of concept, our recent data reveals a novel role of proteostasis-imbalance in COPD pathogenesis. Briefly, cigarette-and biomass-smoke induced proteostasis-imbalance may aggravate chronic inflammatory-oxidative stress and/or protease-anti-protease imbalance resulting in pathogenesis of severe emphysema. In contrast, pathogenesis of other chronic lung diseases like ΔF508-cystic fibrosis (CF), α1-anti-trypsin-deficiency (α -1 ATD) and pulmonary fibrosis (PF) is regulated by other proteostatic mechanisms, involving the degradation of misfolded proteins (ΔF508-CFTR/α1-AT-Z variant) or regulating the concentration of signaling proteins (such as TGF-β1) by the ubiquitin-proteasome system (UPS). The therapeutic strategies to correct proteostasis-imbalance in misfolded protein disorders such as ΔF508-CF have been relatively well studied and involve strategies that rescue functional CFTR protein to treat the underlying cause of the disease. While in the case of COPDemphysema and/or PF, identification of novel proteostasis-regulators that can control inflammatory-oxidative stress and/or protease-anti-protease balance is warranted.

KW - Autophagy

KW - Chronic obstructive pulmonary disease (COPD)

KW - Cigarette smoke (CS)

KW - Emphysema

KW - Proteostasis-imbalance

KW - Proteostasis-regulators

UR - http://www.scopus.com/inward/record.url?scp=84863506784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863506784&partnerID=8YFLogxK

M3 - Article

C2 - 22697347

AN - SCOPUS:84863506784

VL - 12

SP - 807

EP - 814

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 7

ER -